Follicle Stimulating Hormone (FSH) Glycosylation in Women: Effect of Estradiol

Status unconfirmed · Phase 2

Conditions studied: Follicle Stimulating Hormone Glycosylation, Urinary FSH21/FSH24 Ratio, Estradiol Effect

In brief

This clinical trial is an investigational research study to determine the ratio of glycosylated FSH21/FSH24 in premenopausal women and postmenopausal women as well as determining if estradiol can increase this ratio in postmenopausal women.

Key facts

Study ID

NCT03868202

Run by

Eastern Virginia Medical School

People needed

10

Starts

2019-07-03

Expected to finish

2020-01-01

Last updated by the study team

2019-07-12

Who can join

Age: 20 and older, up to 55. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Premenopausal (Age 20-30):
• Age between 20 - 30 years old
• Not on oral, transdermal or vaginal hormonal contraception with last use greater than 2 months (non-hormonal IUD okay)
• At least 6 weeks after removal of subdermal contraceptive implant
• At least 9 months from the last hormonal contraceptive injection
• Regular menses with a 26-32 day interval
• Willingness to abstain from heterosexual intercourse or use barrier contraception during the study
• No serious medical illness
• Not on medication(s) effecting ovarian function
• Screening ultrasound on cycle day 12-14 with at least 1 follicle measuring >12mm.
• Normal pap smear within the last 3 years, if indicated (report needed)
• Postmenopausal (Age 45-60):
• Age between 45-60 years old
• Last spontaneous menstrual period >1 year
• Vaginal pH > 5.0
• No contraindications to hormonal replacement therapy
• No major medical condition/current medication(s) that would impact use of hormone replacement therapy
• Never have been on hormone replacement therapy or last use greater than 6 months
• Mammogram within the last 1 year that is normal (report needed)
• Pap smear within the last 3-5 years that is normal (report needed)
• Willing to use hormone replacement therapy

You may not qualify if…

• Premenopausal (Age 20-30):
• Uncorrected endocrinopathy affecting ovarian function (i.e.: Prolactinoma, thyroid disease)
• Medications affecting the hypothalamic-pituitary-ovarian axis.
• Screening ultrasound with no follicles measuring ≥11 mm
• History of pelvic surgery
• Current abnormal pap smear requiring intervention
• Postmenopausal (Age 45-60):
• Last menstrual period <1 year
• Contraindication to hormone replacement therapy
• Use of exogenous hormone replacement therapy in the last 6 months
• Significant medical disease or current medication use that can impact estrogen metabolism
• Unwilling or unable to use transdermal estrogen and oral progestin.
• Allergy to transdermal estrogen and oral progestin.
• Unexplained vaginal bleeding within the last 6 months.

Where it is running

• Jones Institute for Reproductive Medicine — Norfolk, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.